Related Experiment Videos
Lepromin skin testing in the classification of Hansen's disease in the United States
W A Krotoski1, T F Mroczkowski, T H Rea
1Laboratory Research Branch, Gillis W. Long Hansen's Disease Center, Carville, Louisiana.
Insights
Leprosy (Hansen's disease) classification can be improved using lepromin skin tests. This study supports their value in the United States for better patient management.
Area of Science:
- Medical Microbiology
- Immunology
- Dermatology
Background:
- Hansen's disease (leprosy) significantly impacts patients physically, psychologically, and socially.
- Clinical classification, ranging from lepromatous to tuberculoid forms, guides prognosis and treatment.
- Lepromin skin testing, using Mycobacterium leprae, is traditionally used in endemic areas but not systematically studied in the U.S.
Purpose of the Study:
- To evaluate the efficacy of lepromin skin testing for classifying Hansen's disease in the United States.
- To determine if lepromin testing can serve as an adjunct to clinical parameters in a hypoendemic population.
Main Methods:
- 38 volunteers (22 Hansen's disease patients, 16 uninfected individuals) were skin tested.
- Standard lepromin preparations were administered to assess immune responses.
Main Results:
- Lepromin skin test results showed potential for differentiating disease forms.
- The study supports the adjunctive value of lepromins for clinical classification in the U.S. hypoendemic population.
Conclusions:
- Lepromin skin testing demonstrates utility as an adjunct diagnostic tool for Hansen's disease in the United States.
- Further systematic studies are warranted to fully integrate lepromin testing into clinical practice for leprosy classification.
Abstract:
Hansen's disease, or leprosy, although a relatively uncommon disease in the United States, continues to be important because of its implications--physical, psychological, and social--for the patient. Prognosis and treatment of the disease are based largely on clinical classification, which ranges from the multibacillary "lepromatous" to the paucibacillary "tuberculoid" forms, depending on the patient's specific immune capabilities. Traditionally, skin testing with lepromins--suspensions of the etiologic agent of Hansen's disease, Mycobacterium leprae--have been used as adjuncts to clinical parameters for classification in endemic areas. However, these have not been systematically studied in the United States. This report describes the results obtained from skin testing 38 volunteers (22 patients and 16 uninfected persons) with standard lepromin preparations. These results support the adjunctive value of lepromins for clinically classifying Hansen's disease in our "hypoendemic" population.